A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CNTO 6785 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2013
At a glance
- Drugs CNTO 6785; CNTO 6785
- Indications Cancer
- Focus Adverse reactions
- 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Mar 2011 Actual initiation date (Feb 2011) added as reported by ClinicalTrials.gov.